• LOGIN
Repository logo

BORIS Portal

Bern Open Repository and Information System

  • Publication
  • Projects
  • Funding
  • Research Data
  • Organizations
  • Researchers
  • LOGIN
Repository logo
Unibern.ch
  1. Home
  2. Publications
  3. Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months
 

Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months

Options
  • Details
BORIS DOI
10.7892/boris.14037
Date of Publication
2012
Publication Type
Article
Division/Institute

Institut für Sozial- ...

Author
Meyrat, P
Safroneeva, Ekaterina
Institut für Sozial- und Präventivmedizin (ISPM)
Schoepfer, A M
Subject(s)

600 - Technology::610...

Series
Alimentary pharmacology & therapeutics
ISSN or ISBN (if monograph)
0269-2813
Publisher
Wiley-Blackwell
Language
English
Publisher DOI
10.1111/apt.12087
PubMed ID
23066911
Description
While rifaximin was able to improve symptoms in patients with irritable bowel syndrome (IBS) in phase III trials, these results are yet to be repeated in phase IV studies.
Handle
https://boris-portal.unibe.ch/handle/20.500.12422/84107
Show full item
File(s)
FileFile TypeFormatSizeLicensePublisher/Copright statementContent
Meyrat AlimentPharmacolTher 2012.pdftextAdobe PDF359.62 KBpublished
BORIS Portal
Bern Open Repository and Information System
Build: 360c85 [14.04. 8:05]
Explore
  • Projects
  • Funding
  • Publications
  • Research Data
  • Organizations
  • Researchers
More
  • About BORIS Portal
  • Send Feedback
  • Cookie settings
  • Service Policy
Follow us on
  • Mastodon
  • YouTube
  • LinkedIn
UniBe logo